WuXi AppTec is planning to invest over $30 million in Beijing-based biopharmaceutical firm CANbridge Pharmaceuticals, as the mainland leading biotech firm ramps up efforts to up stakes in China’s orphan disease treatment market.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
